drugset / Trial / NCT03799913
MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
Phase 0
Unknown
20 enrolled
Zhejiang University
Hrain Biotechnology Co., Ltd. · collabSecond Affiliated Hospital, School of Medicine, Zhejiang University · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to study the feasibility and efficacy of anti-MESO antigen receptors (CARs) T cell therapy for relapsed and refractory ovarian cancer.
Timeline
- Start
- 2019-04-10
- Primary completion
- 2021-10
- Completion
- 2022-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-MESO CAR-T cells | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |